The global medical community is developing the COVID-19 vaccine at an unprecedented speed and scale, and the governments of various countries have great expectations for the vaccine to be released and put into use. ล่าสุด, several vaccines under development in the world have been reported frequently. Last month, several well-known vaccines announced the effectiveness of Phase III clinical trials; On December 2, the British government approved the use of COVID-19 vaccine developed by Pfizer and German biotechnology companies; Mardner also announced that it will test COVID-19 vaccine on children … Despite this, Nature pointed out in the report that this does not mean that the vaccine will be fully vaccinated soon. Before that, solving the problems of vaccine hesitation, supply logistics, distribution, pricing and payment will help clear the obstacles.
Pfizer Pharmaceuticals Co., จำกัด. announced on November 9 that the COVID-19 vaccine developed by Pfizer in cooperation with German Biotechnology Company was more than 90% effective in Phase III clinical trials. The Independent reported on November 26th that American pharmaceutical company Mardner announced that the candidate COVID-19 vaccine developed by them was more than 90% มีประสิทธิภาพ. นอกจากนี้, Oxford University and AstraZeneca Company also claimed that the average curative effect of a candidate COVID-19 vaccine developed by them was 70.4%. Early studies have shown that these candidate vaccines can stimulate the immune response. The latest experiment proves that this immune response can protect people from COVID-19.
On December 2nd,
the British government announced that its Medicines and Health Products Administration (
MHRA)
had approved the use of COVID-19 vaccine developed by Pfizer and German biotechnology companies,
which will be launched in Britain from next week.
This urgent authorization cleared the way for vaccine deployment in Britain!
On November 30th, เวลาท้องถิ่น,
American Mardner Company applied to the US Food and Drug Administration (อย.)
for emergency use of its candidate vaccine,
saying that its vaccine was effective and there was no “
serious safety problem”
during the trial.
According to a report in the Capitol Hill Daily on the 2nd,
Mardner Company said that it would recruit 3,000
teenagers aged 12-17
to test COVID-19 vaccine to evaluate the safety of single dose vaccine,
and the results are expected to be announced in 2022.
